Samsung Biologics Co.,Ltd. (207940.KS)

790,000.00 +14,000.00 (+1.80%) At close: 03:30PM KST

Samsung Biologics Co.,Ltd.

300, Songdo Bio-daero
Yeonsu-gu
Incheon 21987
South Korea
82 3 2455 3114
https://samsungbiologics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John Chongbo Rim	CEO, President & Chairman of Board	3.12B	N/A	1961
Mr. Dong-Joong Kim	CFO, Executive VP, MD & Director	666M	N/A	1965
Dr. Tae-Han Kim Ph.D.	Executive Director	2.19B	N/A	1957
Dr. Namjin Chung Ph.D.	Executive VP and Head of Bio R&D Centre & CSO	N/A	N/A	N/A
Mr. Hyung Woo Moon	Vice President & Head of Legal Compliance Team	N/A	N/A	1970
Mr. James J. Choi	Executive VP, Chief Marketing Officer & Head of Sales Support Center	569M	N/A	1967
Mr. Yong Park	Vice President, CHRO & Head of HR Support Center	N/A	N/A	1974
Dr. Brian Hosung Min Ph.D.	Executive VP & Head of CDO Development Center	N/A	N/A	N/A
Mr. Heekyun Lim	VP & Head of Business Consulting Team	N/A	N/A	1975
Dr. Kun Lo Ph.D.	Executive VP & Head of EPCV Center	N/A	N/A	1963

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, Contract Development and Manufacturing Organization Business, and Biopharmaceutical Development and Commercialization Business. It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Corporate governance

Samsung Biologics Co.,Ltd.’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.